Eupraxia Pharmaceuticals logo
Eupraxia Pharmaceuticals
EPRX | NASDAQ
Chart Builder DCF Calculator
$7.34
-$0.81 (-9.94%)
At close: Nov 16, 2026, 4:00 PM ET
$7.34
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Eupraxia Pharmaceuticals Company Profile

Company profile explained

Company Profile

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Key Executives

Name Position
James A. Helliwell FRCPC Chief Executive Officer & Director
Alexander John Rothwell Chief Financial Officer
Alex Therien Executive VP of R&D
Jeffrey Millard Executive Vice President of Technical Operations
Jeymi Tambiah Chief Medical Officer
Paul Anthony Brennan Chief Corporate Development Officer
Wajida Leclerc CHRP Executive Vice President Corporate Services & People

Latest SEC Filings

Date Type Title
Oct 22, 2026 6-K Filing
Oct 15, 2026 6-K Filing
Oct 09, 2026 6-K Filing
Sep 30, 2026 6-K Filing
Sep 08, 2026 6-K Filing
Sep 02, 2026 SUPPL Filing
Aug 24, 2026 EFFECT Filing
Aug 19, 2026 F-10/A [Amend] Filing
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 6-K Filing
View All SEC Filings ➞
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals logo
Country Canada
IPO Date Apr 5, 2024
Industry Biotechnology
Sector Healthcare
Employees 49
CEO James A. Helliwell

Contact Details

2067 Cadboro Bay Road Victoria, BC V8R 5G4 Canada

Stock Details

Ticker Symbol EPRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001581178
CUSIP Number 29842P105
ISIN Number CA29842P1053
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.